Profiel
Christine Welch worked as a Senior Director at Gilead Sciences, Inc. She then worked as a Senior Director-Regulatory Affairs at Achaogen, Inc. from 2011 to 2012.
Prior to that, she worked as a Senior Director-Regulatory Affairs at Alexza Pharmaceuticals, Inc. from 2008 to 2011.
Welch received an undergraduate degree from The University of Liverpool and a graduate degree from Newcastle University.
Eerdere bekende functies van Christine Welch
| Bedrijven | Functie | Einde |
|---|---|---|
| ALEXZA PHARMACEUTICALS, INC. | Algemeen Adviseur | 01-01-2011 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
| ACHAOGEN | Algemeen Adviseur | - |
Opleiding van Christine Welch
| The University of Liverpool | Undergraduate Degree |
| Newcastle University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Alexza Pharmaceuticals, Inc.
 Alexza Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexza Pharmaceuticals, Inc. is a pharmaceutical company. It focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are AZ-002 and AZ-007. The company was founded by Alejandro C. Zaffaroni in 2000 and is headquartered in Mountain View, CA. | Health Technology |
